Inebilizumab is the first FDA-approved therapy for immunoglobulin G4–related disease (IgG4-RD) in adults, based on data from the MITIGATE trial. Inebilizumab significantly reduced the risk of flares and achieved flare-free, corticosteroid-free, complete remission in patients with IgG4-RD. The safety profile was consistent with prior data for other indications. Ongoing efforts include increasing awareness of IgG4-RD for earlier diagnosis and treatment access.

Source: Amgen